Prostate cancer is the most common urologic cancer, with PSA screening reducing mortality by up to 20% in men aged 55–69. Bladder cancer incidence is stable, with early detection through urine ...

Experts discuss the evolving landscape of chemotherapy and immunotherapy options for patients with non-muscle invasive bladder cancer (NMIBC).

Experts discuss current trial data from several studies on non-muscle invasive bladder cancer (NMIBC). EP: 1. A Comprehensive Overview of NMIBC EP: 2. Standard of Care: Staging Considerations and ...

The trial explores opaganib and darolutamide combination in mCRPC, using PCPro biomarker for patient selection. Opaganib targets sphingosine kinase-2, potentially overcoming resistance to androgen ...

Prostate cancer incidence in California rose significantly from 2011 to 2021, especially in distant stage cases, with non-Hispanic Black men most affected. Mortality rates for prostate cancer ...

The 2025 Urology Residency Match connected 403 applicants to 148 programs, achieving a 76% match rate with no vacancies left unmatched. Demographics of matched applicants included 51.1% White, 26.1% ...

"We need to think carefully about what we're putting in our body and what the regulations are about natural products that we ingest," says Channing J. Paller, MD. In this video, Channing J. Paller, MD ...

"There are actually no data to support that 1 neuromodulation is better than another based on disease severity, and this is based on the systematic review done for the OAB guideline," says Anne ...

MiR-371a-3p demonstrates high sensitivity and specificity, outperforming traditional tumor markers in testicular cancer diagnosis and monitoring. MiR-371a-3p shows potential in early relapse detection ...

Acute toxicity in prostate cancer radiotherapy is linked to increased late toxicity and reduced quality of life. Innovations like smaller treatment margins aim to minimize early side effects and ...

"Wearable devices are increasingly being used to understand and improve male sexual dysfunctions," write the authors. Smerina is an OMS-3 at the Dr. Kiran C. Patel College of Osteopathic Medicine at ...

"This study provides a comprehensive review of the role of natural products as complementary treatments for prostate cancer," says Channing J. Paller, MD. In this video, Channing J. Paller, MD, gives ...